[HTML][HTML] Nrf2 mediated signaling axis in heart failure: potential pharmacological receptor
P Cheng, X Wang, Q Liu, Y Hu, E Dai, M Zhang… - Pharmacological …, 2024 - Elsevier
Heart failure (HF) has emerged as the most pressing health concerns globally, and extant
clinical therapies are accompanied by side effects and patients have a high burden of …
clinical therapies are accompanied by side effects and patients have a high burden of …
NRF2 in cardiovascular diseases: a ray of hope!
R Vashi, BM Patel - Journal of cardiovascular translational research, 2021 - Springer
Heart failure is a worldwide pandemic influencing 26 million individuals worldwide and is
expanding. Imbalanced redox homeostasis in cardiac cells alters the structure and function …
expanding. Imbalanced redox homeostasis in cardiac cells alters the structure and function …
The dark side of Nrf2 in the heart
Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) is a critical transcription factor that
regulates the expression of over 1000 genes in the cell under normal and stressed …
regulates the expression of over 1000 genes in the cell under normal and stressed …
Targeting Nrf2 Signaling Pathway: New Therapeutic Strategy for Cardiovascular Diseases
Q Wu, J Yao, M Xiao, X Zhang, M Zhang… - Journal of Drug …, 2024 - Taylor & Francis
Cardiovascular diseases (CVDs) are the leading cause of death globally, with oxidative
stress (OS) identified as a primary contributor to their onset and progression. Given the …
stress (OS) identified as a primary contributor to their onset and progression. Given the …
The role of Nrf2‐mediated pathway in cardiac remodeling and heart failure
S Zhou, W Sun, Z Zhang… - Oxidative medicine and …, 2014 - Wiley Online Library
Heart failure (HF) is frequently the consequence of sustained, abnormal neurohormonal,
and mechanical stress and remains a leading cause of death worldwide. The key …
and mechanical stress and remains a leading cause of death worldwide. The key …
The role of Nrf2 in cardiovascular function and disease
S Satta, AM Mahmoud, FL Wilkinson… - Oxidative medicine …, 2017 - Wiley Online Library
Free radicals, reactive oxygen/nitrogen species (ROS/RNS), hydrogen sulphide, and
hydrogen peroxide play an important role in both intracellular and intercellular signaling; …
hydrogen peroxide play an important role in both intracellular and intercellular signaling; …
Natural allies for heart health: Nrf2 Activation and cardiovascular disease management
The term “cardiovascular diseases”(CVD) refers to various ailments that affect the heart and
blood vessels, including myocardial ischemia, congenital heart defects, heart failure …
blood vessels, including myocardial ischemia, congenital heart defects, heart failure …
An overview of the mechanisms and novel roles of Nrf2 in cardiovascular diseases
S Jiang, Y Yang, T Li, Z Ma, W Hu, C Deng… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine zipper (bZIP)
transcription factor of the cap'n'collar (CNC) family that is present in various organs. The …
transcription factor of the cap'n'collar (CNC) family that is present in various organs. The …
Activation of Nrf2 signaling: A key molecular mechanism of protection against cardiovascular diseases by natural products
X Wu, J Wei, Y Yi, Q Gong, J Gao - Frontiers in Pharmacology, 2022 - frontiersin.org
Cardiovascular diseases (CVD) are a group of cardiac and vascular disorders including
myocardial ischemia, congenital heart disease, heart failure, hypertension, atherosclerosis …
myocardial ischemia, congenital heart disease, heart failure, hypertension, atherosclerosis …
Targeting the Nrf2 pathway against cardiovascular disease
J Li, T Ichikawa, JS Janicki, T Cui - Expert opinion on therapeutic …, 2009 - Taylor & Francis
Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor that controls the basal and
inducible expression of a battery of antioxidant genes and other cytoprotective Phase II …
inducible expression of a battery of antioxidant genes and other cytoprotective Phase II …